



A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration- Resistant Prostate Cancer Previously Treated With Chemotherapy

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over This study is NOT accepting healthy

volunteers

Inclusion Criteria:

- diagnosis of adenocarcinoma of the prostate - evidence of progressive disease - completed requirements for previous treatment - may not be able to do strenuous activity but able to walk and able to carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- history of central nervous system (CNS) metastasis - significant side effects from previous treatment that haven't resolved - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Interventions:

Drug: Abiraterone, Drug: Cabazitaxel, Drug: Enzalutamide, Drug: Xaluritamig

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Metastatic Castration-resistant Prostate Cancer, Prostate

More Information

Description: This is a research study designed to test how well a new medication (xaluritamig) works compared to other treatments for people with metastatic castration-resistant prostate cancer. These patients have already been treated with a certain chemotherapy. Participants will be randomly assigned to one of two groups: xaluritamig or either cabazitaxel (existing cancer treatment) or another treatment chosen by the doctor. The goal of the study is to find out which treatment is more effective and safer for patients.

Study Contact: Nicholas Zorko - zorko004@umn.edu

Principal Investigator: Nicholas Zorko

Phase: PHASE3

IRB Number: STUDY00023844

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.